Greenwich LifeSciences, Inc. — FY2023 Form 10-K
Business context and reporting period. This annual report covers the fiscal year ended December 31, 2023. Greenwich is a clinical-stage biotechnology company with no product sales or approved products. Its lead candidate, GLSI-100 (GP2 plus GM-CSF), is being studied to prevent breast cancer recurrence. The company reported that its Phase III Flamingo-01 trial was enrolling in the U.S. and Europe, with plans to expand to as many as 150 sites.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $7.70 million | $6.48 million |
| General and administrative expense | $1.63 million | $1.56 million |
| Total operating expenses | $9.33 million | $8.04 million |
| Net loss | $8.89 million | $7.83 million |
| Net loss per share | $0.69 | $0.61 |
| Net cash used in operating activities | $6.48 million | $6.20 million |
| Cash at year-end | $6.99 million | $13.47 million |
Cash declined by $6.48 million during 2023. The company reported total assets of $6.99 million, total liabilities of $294,406, and stockholders’ equity of $6.70 million at year-end. It reported no investing cash flows and no financing cash flows in 2023; 2022 financing outflows of $7.54 million reflected share repurchases. The filing reports no material contractual obligations beyond employment and shareholder agreements and the GP2 license. No debt balance is presented, though current liabilities include accounts payable and accrued interest.
There is no meaningful product gross margin because the company has no revenue. The filing says year-end cash was expected to fund operating and capital requirements for at least 12 months from the filing date, but also says substantial additional capital is needed to complete development and pursue approval. The auditor highlighted recurring losses, limited cash flow, and accumulated deficit as conditions raising substantial doubt about the company’s ability to continue as a going concern.
Material changes and clinical developments
- R&D expense rose 19%, primarily due to higher Phase III trial costs; G&A increased 4%, mainly due to stock-based compensation.
- Net loss increased by about $1.07 million year over year. Operating cash use increased by about $0.28 million.
- The company disclosed inconsistencies in Phase IIb trial records while preparing its comprehensive study report. A possible recurrence in a treated patient was identified in Q4 2023 but was not confirmed in the database or a key recurrence form. The company is seeking confirmation from HJF and treating clinicians. It also noted a reported control-arm recurrence absent from data received from HJF.
- Management stated that a treated-arm recurrence, if confirmed, would change the reported recurrence reduction from 100% to 80% in the relevant efficacy population and increase the p-value. The Phase IIb Kaplan-Meier curve and p-value remain subject to change pending final data review.
- After year-end through April 10, 2024, the company sold 30,244 shares through its ATM program for $387,490 gross and $348,741 net proceeds.
Outlook, risks, and unusual items
The filing provides no formal revenue or earnings guidance. Management expects ongoing losses and significant spending on clinical development, manufacturing, and operations. It estimates that completing a Phase III interim analysis and filing a U.S. BLA could cost more than $30 million, while noting that trial costs may be adjusted. No financing commitment is disclosed; the company may seek equity or debt financing, partnerships, licensing arrangements, or other strategic alternatives.
- Clinical and regulatory risk: Flamingo-01 must establish safety and efficacy; enrollment, trial execution, data quality, regulatory review, and approval remain uncertain. FDA clinical holds are possible, although the company reported that a prior hold was removed in July 2022.
- Trial-data uncertainty: Phase IIb data are being reconciled, and the filing describes discrepancies and a possible treated-arm recurrence. Prior results are not necessarily predictive of Phase III outcomes.
- Funding and going concern: cash is limited relative to the stated development needs, and the auditor cited substantial doubt about continuing as a going concern.
- Supply and partner dependence: the company relies on third parties for manufacturing, clinical operations, and the supply of GM-CSF, which is available from a single manufacturer. GP2 rights are licensed from HJF, with maintenance fees, potential milestones, royalties, and patent-expense reimbursement obligations.
- Control weakness: management concluded disclosure controls and internal control over financial reporting were ineffective at December 31, 2023, citing inadequate segregation of duties and insufficient written accounting, IT, and reporting procedures. The company is developing a remediation plan.
- Other risks: competition, patient recruitment, reimbursement, intellectual-property protection, cybersecurity, and the company’s small workforce (three full-time and four part-time employees as of April 10, 2024).
Most important facts to verify
- Current cash, expected burn rate, financing plans, and the actual runway relative to the auditor’s going-concern warning.
- Final Phase IIb recurrence and censoring data, including resolution of the possible treated-arm recurrence and control-arm data discrepancy.
- Flamingo-01 enrollment, trial costs, interim-analysis timing, site expansion, and any subsequent regulatory developments.
- Progress in remediating material weaknesses in internal controls and any subsequent changes to disclosure-control effectiveness.
- Reliability and availability of GM-CSF and contract manufacturing, and the status of the HJF license and related obligations.